Baxter International: The Gains Can Continue, But Should Slow

Baxter International has shown early signs of a turnaround, with improving execution and raised revenue guidance supporting cautious optimism. BAX's valuation has expanded from distressed levels, now trading at ~13x earnings and ~9.5x EV/EBITDA, yet remains attractive if growth continues. Management's focus on operational improvements, cost savings, and a conservative outlook suggests potential for further upside if EPS growth materializes. Risks remain around execution, leverage, and business headwinds, but deleveraging and possible multiple expansion offer a still-compelling, though less asymmetric, risk/reward.

The bull case for Baxter International Inc. (BAX) stock has changed in the last couple of months. As shares bounced along multi-year lows in late 2025 and into this year, the argument was that the business